volatil ahead stock hold higher floor
refin stock regain lost ground earn beat estim activ fall
mainten season support margin compress around ye new
capac come on-line favor dk play upcom margin strength see
outperform follow margin compress would add
outperform rate stock pullback given upcom imo tailwind
link full note
believ result mark begin oper posit inflect
potenti momentum build toward recent announc decemb investor
day minim buysid sell-side support remain expect shift estim
begin move higher valuat biggest investor debat pt impli
ftm ev/sal modest recoveri histor level
link full note
pleas see addendum report import disclosur
see econom ep gain least thru solid cash flow allow
dividend hike ytd offer peer-high dividend cash flow
yield net buy vs peer set well upbeat
link full note
juli mobil game monthli analysi suggest monet
king glu zynga remain steadi ea western market mobil perform
remain sluggish continu view growth sustain mobil game
underappreci investor
link full note
updat model reflect galafold price releas morn
encourag commerci strategi launch readi glean
multipl call diseas awar patient id program progress
key continu believ consensu guidanc number
achiev pt remain still best idea
link full note
updat estim reflect assumpt busi divestitur time includ
closur hr consulting/actuari busi today half quarter contribut
previous includ model off-set later year
plan sale government servic busi assum occur quarter margin
assumpt also tweak pt rate maintain
link full note
europ weather tcg tui tvpt also hurt ad roi improv am buy
travelclick jin jiang-l grp buy hna radisson cvc
brazil juli book brl vs abnb target night biz
travel vs today detail result
link full note
reflect ep bookings/fx pressur lead revenu toward lower end
guid rang cost takeout still outpac top line declin support ep
increas toward top rang anticip cost out-performance support posit bia
share novemb analyst day
link full note
homolog report net loss cash
includ net proce ipo lead pku gene therapi candid
continu advanc toward ind file clinic trial initi first
data anticip pku gene-edit candid nomin
ind-en studi set remain outperform
link full note
cfo exit stage left great
announc press releas morn longtim cfo david well
step follow search replac believ still earli
stage expect smooth transit successor given well stay
board throughout process forese materi chang busi
reiter outperform pt
link full note
report larg in-lin result howev significantli reduc
revenue/ebitda guidanc wors fear respect
easi simpli say compani guid strong gate remain unclear
us success compani expand strategi still weak
link full note
today host call tilray ceo brendan kennedi cfo mark castaneda
provid key highlight insight think potenti addit form
factor singl serv edibl and/or vape prior octob posit although
ontario announc even suggest slower expect ramp
provinc note replay event access
link full note
usap offer above-p revenu ep growth favor aero demand
sale stabl rise commod nickel firm belong select group
specialti metal convert incl recent equiti offer debt refi
strengthen cash profil see upward revis potenti initi
outperform rate price target ev/ebitda yield
link full note
report net loss end cash
rituximab dose expans cohort broaden includ altern rituximab dose
data expect around phase trial sea-bcma mm
rituximab nhl remain on-track data ind
trastuzumab cancer activ remain market perform
link full note
revenu st net loss wider media agenc revenu
declin lower averag ad spend ai revenu grew y/i declin q/q
lower-than-expect legal project revenu veri announc two acquisit
almost revenu defer detail call cut
estim pt vs sale
link full note
math assumpt around newco jean remainco stand-alone multipl
suggest transact littl arbitrag valu exist compani
creat strateg focu stand-alone compani total long-term
valu creation sotp suggest rang though upsid van
north face could move consensu estim higher
link full note
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
